Literature DB >> 10223336

Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles.

M P Rudolf1, J D Nieland, D M DaSilva, M P Velders, M Müller, H L Greenstone, J T Schiller, W M Kast.   

Abstract

It has been postulated that upon binding to a cell surface receptor, papilloma virus-like particles (VLPs) gain entry into the cytosol of infected cells and the capsid proteins L1 and L2 can be processed in the MHC class I presentation pathway. Vaccination of mice with human papilloma virus-like particles consisting of capsid proteins L1 and L2 induced a CD8-mediated and perforin dependent protective immune response against a tumor challenge with human papilloma virus transformed tumor cells, which express only minute amounts of L1 protein. Here we show that HPV16 capsid proteins stimulate a MHC class I restricted CTL response with human peripheral blood lymphocytes (PBL) in vitro. The vigorous response was specific for VLP-infected target cells and was MHC class I restricted. Moreover we show the presence of at least one HLA-A*0201 restricted CTL epitope within the HPV-16 capsid proteins by using a VLP-'infected' HLA-A*0201 transfected human cell line as target cells. These results demonstrated that VLPs can induce a HPV16 capsid protein-specific immune response in humans, allowing the monitoring of immune responses induced by vaccines based on chimeric VLPs carrying additional immunogenic peptides or proteins in therapeutical applications in human patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10223336     DOI: 10.1515/BC.1999.045

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  9 in total

1.  Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia.

Authors:  Jo-Ann S Passmore; Michelle Milner; Lynnette Denny; Candice Sampson; Dianne J Marais; Bruce Allan; Pam P Gumbi; Inga I Hitzeroth; Edward P Rybicki; Anna-Lise Williamson
Journal:  Immunology       Date:  2006-10-09       Impact factor: 7.397

2.  Influence of Brucella abortus lipopolysaccharide as an adjuvant on the immunogenicity of HPV-16 L1VLP vaccine in mice.

Authors:  Zahra Kianmehr; Hoorieh Soleimanjahi; Susan Kaboudanian Ardestani; Fatemeh Fotouhi; Asghar Abdoli
Journal:  Med Microbiol Immunol       Date:  2014-09-04       Impact factor: 3.402

Review 3.  Prevention of cervical cancer with vaccines.

Authors:  S S Im; B J Monk; L P Villarreal
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

4.  A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response.

Authors:  Nadja Thönes; Anna Herreiner; Lysann Schädlich; Konrad Piuko; Martin Müller
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

5.  Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.

Authors:  Stefania Bellone; Karim El-Sahwi; Emiliano Cocco; Francesca Casagrande; Marilisa Cargnelutti; Michela Palmieri; Eliana Bignotti; Chiara Romani; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Alessandro D Santin
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

6.  Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88.

Authors:  Rongcun Yang; Francisco Martinez Murillo; Hengmi Cui; Richard Blosser; Satoshi Uematsu; Kiyoshi Takeda; Shizuo Akira; Raphael P Viscidi; Richard B S Roden
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

7.  Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine.

Authors:  Rebecca T Emeny; Cosette M Wheeler; Kathrin U Jansen; William C Hunt; Tong-Ming Fu; Judith F Smith; Stefani MacMullen; Mark T Esser; Xavier Paliard
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

Review 8.  Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.

Authors:  Balasubramanyam Karanam; Subhashini Jagu; Warner K Huh; Richard B S Roden
Journal:  Immunol Cell Biol       Date:  2009 May-Jun       Impact factor: 5.126

9.  Cell-permeable capsids as universal antigen carrier for the induction of an antigen-specific CD8+ T-cell response.

Authors:  Sami Akhras; Masako Toda; Klaus Boller; Kiyoshi Himmelsbach; Fabian Elgner; Marlene Biehl; Stephan Scheurer; Meike Gratz; Stefan Vieths; Eberhard Hildt
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.